Amgen All Financial Data in US $ (mln)
Worldwide  
  Overview  


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile
Profile Amgen (AMGN) is a California based biotechnology company, focused on development and commercialisation of human therapeutics for grievous illnesses, based on advances in cellular and molecular biology.
Listed or Private Company Listed
Company Classification Global Majors; Biotechnology
Company Website Website

Full Company Profile Information

EventAnalyzer - Last Key Event
Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
8/16/2010 16 Aug: Deutsche Bank initiates coverage with a "hold" rating and price target of $57, citing continued concerns about the impact from the US healthcare reform and EU pricing cuts which could erode the company's sales, and stating that it is unlikely the company will report positive data for osteoporosis treatment, denosumab. 51,834 -1.7% -901
Top 3 Products (Worldwide Sales 2007/08)
Annual Sales WW - Sales Growth per Year (%)
Rank1 Product Generic Name Therapeutic Subcategory 2007 2008 2008
1 Enbrel etanercept Other anti-rheumatics 3,2302 3,5983 +11%
2 Neulasta pegfilgrastim Immunostimulants 3,0004 3,3185 +11%
3 Aranesp darbepoetin alfa Anti-anaemics 3,6146 3,1377 -13%
Note: Shaded Cells8
RX Sales Chart
Amgen Data Growth
2007 2008 2008
 Revenues By Segment
  Pharmaceuticals
     Pharmaceuticals Sales (In-depth)
       Rx & OTC Pharmaceuticals
         Prescription (Rx) Pharmaceuticals 14,311 14,687   +3%  
Therapy Area Focus in 2008
Amgen
2008
 WW Rx & OTC Sales By Therapy Area
  Main Categories
     Blood 5,610
     Endocrine 597
     Musculoskeletal 3,652
     Oncology & Immunomodulators 4,828
     Other Rx & OTC Pharma9 0
EvaluatePharma® Coverage of Marketed and Pipeline Products
Product Count
Amgen 10 143

Register to access more FREE content:

  • 2009 Product Sales analysis
  • 2009 Pharmaceutical Sales
  • 2009 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

 
EP Vantage - last 6 months
Preview - ESC to throw up more than just the hot topics (August 26, 2010)
Therapeutic focus - Vectibix failure leaves few new options for head and neck cancer (August 16, 2010)
Amgen will be disappointed with Vectibix failure (August 12, 2010)
Medicare dialysis rules to re-shape ESA market (July 28, 2010)
Safety concerns narrow tanezumab’s potential further (July 21, 2010)

Displaying 5 out of a possible 14 unique stories.
Results Sorted By date
Display All Stories